Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.2K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

134.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
134.2K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.8K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.2K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.2K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

6.0K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
6.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing antidiabetics for Alzheimer's disease and related neurodegenerative disorders: Translational challenges and role of nanoparticle-mediated CNS targeting.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Simultaneous inhibition of cholinesterase and antagonism of histamine H3 receptors alleviates cognitive deficits and mitigates apoptosis in scopolamine-induced amnesia in mice.

Frontiers in behavioral neuroscience·2026
Same author

The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice.

Scientific reports·2026
Same author

The role of interleukin-37 and interleukin-38 in the development and remission of autism spectrum disorder: a comprehensive review of neuroinflammatory mechanisms and potential therapeutic implications.

Frontiers in immunology·2025
Same author

The Emerging Role of Phosphodiesterase Inhibitors in Fragile X Syndrome and Autism Spectrum Disorder.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Effects of apigenin on the function of human α7-nicotinic acetylcholine receptors expressed in <i>Xenopus</i> oocytes.

Natural product research·2025

Related Experiment Video

Updated: Mar 30, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K

Cherry-picked ligands at histamine receptor subtypes.

Bassem Sadek1, Holger Stark2

  • 1Department of Pharmacology and Therapeutics, College of Medicine & Health Sciences, United Arab Emirates University, PO Box 17666, Al Ain, United Arab Emirates.

Neuropharmacology
|November 20, 2015
PubMed
Summary

Histamine receptors (H1-H4Rs) are key targets for treating diseases. This review details novel agonists and antagonists, aiding optimal drug selection based on affinity and efficacy.

Keywords:
AgonistsAntagonistsH1–H4 receptorsHistamine

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.1K

Related Experiment Videos

Last Updated: Mar 30, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.1K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Histamine mediates physiological effects via four receptors (H1-H4Rs).
  • Histamine receptors are crucial therapeutic targets for various diseases, including allergies and neurodegenerative disorders.
  • Medicinal chemistry efforts have yielded diverse histamine receptor ligands.

Purpose of the Study:

  • To provide an overview of histamine receptor subtypes (H1-H4Rs).
  • To review developed agonists and antagonists targeting histamine receptors.
  • To highlight structure-activity relationships, chemical diversity, and pharmacological profiles of novel ligands.

Main Methods:

  • Literature review of histamine receptor research.
  • Analysis of chemical structures and properties of histamine receptor ligands.
  • Evaluation of structure-activity relationships for agonists and antagonists.

Main Results:

  • Detailed overview of H1-H4Rs and their associated ligands.
  • Identification of key chemical diversities and pharmacophores.
  • Highlighting of pharmacological profiles for innovative agonists and antagonists.

Conclusions:

  • The review supports informed ligand selection for histamine receptors.
  • Affinity, selectivity, and efficacy data are crucial for optimizing drug development.
  • Understanding ligand properties facilitates targeted therapeutic strategies.